Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 4/20 | 0.49 |
| ▸ | CYSLTR1 | Q9Y271 | 4/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.48 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.48 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL201961 | 1.00 | CYSLTR2 (0.49) | CYSLTR2CYSLTR1PTGER1PTGER4PTGER3 | |
| SCHEMBL29517073 | 1.00 | CYSLTR2 (0.49) | CYSLTR2CYSLTR1PTGER1PTGER4PTGER3 | |
| SCHEMBL30497375 | 1.00 | CYSLTR2 (0.49) | CYSLTR2CYSLTR1PTGER1PTGER4PTGER3 | |
| SCHEMBL14843923 | 0.90 | CYSLTR2 (0.46) | CYSLTR2CYSLTR1PTGER1PTGER4PTGER3 | |
| SCHEMBL27935898 | 0.90 | CYSLTR2 (0.46) | CYSLTR2CYSLTR1PTGER1PTGER4PTGER3 | |
| SCHEMBL9108250 | 0.90 | CYSLTR2 (0.46) | CYSLTR2CYSLTR1PTGER1PTGER4PTGER3 | |
| SCHEMBL9108247 | 0.90 | CYSLTR2 (0.46) | CYSLTR2CYSLTR1PTGER1PTGER4PTGER3 | |
| SCHEMBL692870 | 0.89 | CYSLTR2 (0.52) | CYSLTR2CYSLTR1PTGER1PTGER4PTGER3 | |
| SCHEMBL692871 | 0.89 | CYSLTR2 (0.52) | CYSLTR2CYSLTR1PTGER1PTGER4PTGER3 | |
| SCHEMBL13992167 | 0.88 | CYSLTR2 (0.47) | CYSLTR2CYSLTR1PTGER1PTGER4PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8617853-B2 | Ketoreductase polypeptides for the production of (S,E)-methyl 2-(3-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-hydroxypropyl)benzoate | CODEXIS, INC. (US) | 2013-12-31 | — | — | US | claimed |
| US-20120184000-A1 | KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF (S,E)-METHYL 2-(3-(3-(2-(7-CHLOROQUINOLIN-2-YL)VINYL)PHENYL)-3-HYDROXYPROPYL)BENZOATE | CODEXIS, INC. (US) | 2012-07-19 | — | — | US | claimed |
| US-8088610-B2 | Ketoreductases for the production of (S,E)-methyl 2-(3-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-hroxypropyl)benzoate | CODEXIS, INC. (US) | 2012-01-03 | — | — | US | claimed |
| EP-2094665-A2 | PREPARATION OF MONTELUKAST AND ITS SALTS | Dr. Reddy's Laboratories Ltd. (IN) | 2009-09-02 | — | — | EP | claimed |
| US-20090155863-A1 | KETOREDUCTASE POLYPEPTIDES AND USES THEREOF | CODEXIS, INC. (US) | 2009-06-18 | — | — | US | claimed |
| WO-2008058118-A2 | PREPARATION OF MONTELUKAST AND ITS SALTS | DR. REDDY'S LABORTORIES, LTD. (IN) | 2008-05-15 | — | — | WO | claimed |
| US-20060223999-A1 | Process for preparing montelukast and precursors thereof | CHEMAGIS LTD. (IL) | 2006-10-05 | — | — | US | claimed |
| CN-117003639-A | Preparation method of methyl o-iodobenzoate | 宿迁盛基医药科技有限公司 | 2023-11-07 | — | — | CN | disclosed |
| CN-116606250-A | Preparation method of key intermediate of montelukast sodium | 江苏阿尔法药业股份有限公司 | 2023-08-18 | — | — | CN | disclosed |
| CN-116514711-A | New synthesis process of key intermediate of montelukast sodium | 江苏阿尔法药业股份有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-116410091-A | Compound for preparing montelukast sodium intermediate, method and related compound application and method for preparing montelukast sodium intermediate | 南京欧信医药技术有限公司 | 2023-07-11 | — | — | CN | disclosed |
| CN-112724082-B | Preparation method of montelukast sodium drug intermediate | 江苏阿尔法药业股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-112724082-A | Preparation method of montelukast sodium drug intermediate | 江苏阿尔法药业有限公司 | 2021-04-30 | — | — | CN | disclosed |
| US-5427933-A | Bioconversion | MERCK & CO., INC. (US) | 1995-06-27 | — | — | US | disclosed |
| US-5270324-A | Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1993-12-14 | — | — | US | disclosed |
| US-5212180-A | Quinoline-containing ketoacids as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1993-05-18 | — | — | US | disclosed |
| US-5204358-A | Antiallergens; antiinflammatory agents; treatment of asthma, rhinitis, bronchitis and skin diseases | MERCK FROSST CANADA, INC. (CA) | 1993-04-20 | — | — | US | disclosed |
| EP-0500360-A1 | Quinoline-containing ketoacids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1992-08-26 | — | — | EP | disclosed |
| US-5104882-A | Leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1992-04-14 | — | — | US | disclosed |
| EP-0399818-A1 | Diarylstyrylquinoline diacids | MERCK FROSST CANADA INC. (CA) | 1990-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155863-A1 | KETOREDUCTASE POLYPEPTIDES AND USES THEREOF | TKT, DCXR, AKR1B1 | CYSLTR2 3723/4885CYSLTR1 3689/4885PTGER1 4410/4885 |
| US-20060223999-A1 | Process for preparing montelukast and precursors thereof | CMA1, LTC4S, LTB4R2 | CYSLTR2 5/4885CYSLTR1 16/4885PTGER1 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.